KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Current Deferred Revenue for 8 consecutive years, with $10.1 million as the latest value for Q2 2025.

  • Quarterly Current Deferred Revenue fell 39.47% to $10.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Jun 2025, down 39.47% year-over-year, with the annual reading at $12.6 million for FY2024, 80.5% down from the prior year.
  • Current Deferred Revenue hit $10.1 million in Q2 2025 for Vir Biotechnology, down from $11.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $262.9 million in Q1 2021 to a low of $10.1 million in Q2 2025.
  • Historically, Current Deferred Revenue has averaged $48.0 million across 5 years, with a median of $16.2 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 5148.08% in 2021 and later crashed 94.1% in 2022.
  • Year by year, Current Deferred Revenue stood at $98.2 million in 2021, then plummeted by 84.2% to $15.5 million in 2022, then soared by 317.95% to $64.9 million in 2023, then tumbled by 80.5% to $12.6 million in 2024, then dropped by 20.07% to $10.1 million in 2025.
  • Business Quant data shows Current Deferred Revenue for VIR at $10.1 million in Q2 2025, $11.9 million in Q1 2025, and $12.6 million in Q4 2024.